placebo.¹ The current analysis assessed objective cough frequency in the pooled population of COUGH-1 and COUGH-2. **Methods** Adults aged ≥ 18 years with CC lasting ≥ 1 year, a diagnosis of RCC or UCC according to CHEST guidelines, and a baseline cough severity visual analog scale score ≥ 40 mm were eligible for COUGH-1 and COUGH-2. Participants were randomized to placebo, gefapixant 15 mg BID, or gefapixant 45 mg BID. Objective cough frequency was measured using the VitaloJAK™ (Vitalograph; Buckinghamshire, England) recording device. Cough frequency endpoints included 24-hour and awake cough frequency assessed through Weeks 12 and 24 (COUGH-1 and COUGH-2, respectively). Data were pooled across trials and analyzed at Week 12 using longitudinal analysis of covariance based on log-transformed data.

Results The pooled population from COUGH-1 and COUGH-2 included 2044 total participants. Baseline 24-hour and awake cough frequency were similar across treatment groups (table 1). Relative reductions in 24-hour and awake cough frequency for gefapixant 45 mg BID vs placebo were 18.6% (95% CI: 9.2, 27.1) and 17.4% (95% CI: 7.5, 26.2), respectively. No differences in serious adverse events (AEs) were observed across treatment groups. The most common AEs with gefapixant were taste related.

Abstract P61 Table 1 Relative Reduction in 24-Hour and Awake Cough Frequency in COUGH-1 and COUGH-2

	Baseline GM, coughs/ h	Week 12 GM, coughs/ h	Model- based GMR, ^a Week 12/ Baseline (95% CI)	Relative reduction in cough frequency vs placebo, % (95% CI)
24-hour cough frequency				
Placebo	20.9	9.9	0.48 (0.44, 0.52)	—
Gefapixant 15 mg BID	19.3	9.1	0.47 (0.43, 0.51)	1.0 (-10.4, 11.2)
Gefapixant 45 mg BID	18.6	7.3	0.39 (0.36, 0.42)	18.6 (9.2, 27.1)
Awake cough frequency				
Placebo	27.7	12.7	0.46 (0.43, 0.50)	—
Gefapixant 15 mg BID	25.3	11.8	0.46 (0.43, 0.51)	- 0.3 (-12.1, 10.3)
Gefapixant 45 mg BID	24.3	9.4	0.38 (0.35, 0.42)	17.4 (7.5, 26.2)

BID, twice daily; GM, geometric mean; GMR, GM ratio.

^aBased on the longitudinal covariance model consisting of the change from baseline in log-transformed coughs/h at each postbaseline visit (up to Week 12) as response.

Conclusions COUGH-1 and COUGH-2 are the largest clinical trials investigating treatment of CC. In this pooled analysis, gefapixant 45 mg BID demonstrated significant reductions in 24-hour and awake cough frequency vs placebo, with no increase in serious AEs.

REFERENCE

- McGarvey, et al. *Eur Respir J.* 2020;**56**(suppl 64):3800.

Please refer to page A192 for declarations of interest related to this abstract.

Breaking barriers in pulmonary rehabilitation and physiotherapy

P62

USE OF A COMPUTER GUIDED CONSULTATION (CLINICAL DECISION SUPPORT SYSTEM) ENABLES DETAILED CHARACTERISATION OF PATIENTS PRESENTING TO A TEACHING CENTRE SLEEP SERVICE AND SHOWS THAT INSOMNIA IS FREQUENTLY REPORTED IN THIS PATIENT GROUP

¹M Ahmad, ¹M Thomas, ¹M Brady, ¹B Chakrabarti, ¹R Angus, ¹M Pearson, ²L Reed, ²E McKnight, ³J Wood, ⁴P England, ⁵S Craig. ¹Liverpool Sleep and Ventilation Service, Liverpool, UK; ²National Services for Health Improvement Ltd, Liverpool, UK; ³University of Liverpool School of Medicine, Liverpool, UK; ⁴Lunghealth Limited, Liverpool, UK

10.1136/thorax-2021-BTSabstracts.172

Background Patients attending primary care with possible Obstructive Sleep Apnoea (OSA) often describe difficulty getting off to sleep or maintaining sleep. This can be mistaken for insomnia by the referring doctor leading to some referrals being rejected, especially if no other information is available. In our service a clinical decision support system (CDSS) has been implemented which allows gathering of more detailed descriptive data and sleep history including insomnia symptoms. We investigated the frequency of initiation and maintenance insomnia in patients attending Liverpool Sleep and ventilation service.

Methods All patients attending Liverpool Sleep and Ventilation service from March- June 2021 were taken through the CDSS, with patients' detailed history, demographics, diagnosis, investigation and treatment documented. All patients answer time to get to sleep, whether they experience difficulty falling asleep, disturbed sleep or nocturia. Output from the database was imported into excel for statistical analysis. Only patients with valid sleep study results were included.

Results A total of 325 patients were reviewed through the CDSS. 282 had a completed sleep study of which 250 had a confirmed diagnosis of OSA, mild, moderate, severe or no evidence of OSA and the remaining 32 had a possible diagnosis of OSA requiring further review. Of the confirmed diagnosis there were a higher proportion of males in the

Abstract P62 Table 1

	OSA (199)	No OSA (51)
Age	52.5	41.6
Male%	59%	29%
BMI	37.4	31.8
ESS	10.4	10.6
AHI	25.3	1.8
ODI	31.7	3
Time >1 hr =1	50 (25%)	12 (24%)
Difficult to get to sleep = 2	118 (59%)	32 (62%)
Difficult to remain asleep = 3	141 (71%)	35 (69%)
Nocturia	1.8	1.3
Sleep induction-->		
1+2 (59)	47 (24%)	12 (24%)
2+3 (119)	91 (46%)	28 (55%)
1+3 (122)	94 (47%)	28 (55%)
1+2+3 (43)	33 (17%)	10 (20%)

OSA group compared with not OSA along with higher AHI and ODI. The BMI were similar between the two groups and there was no difference in the ESS. We then compared the symptoms of initiation and maintenance insomnia between the two groups. 75% of patients with confirmed diagnosis of OSA experienced insomnia symptoms. We found that there was no difference in symptoms of time to get to sleep, difficulty to get to sleep and difficulty to remain asleep between those with OSA and those with no evidence of OSA. (see table 1).

Conclusion This suggests there is a large proportion of patients presenting to our service with difficulty falling or staying asleep. There are a similar proportion of patients describing these initiation and maintenance insomnia symptoms in those diagnosed with OSA compared to those where OSA was excluded.

P63 ASSESSING WHICH PATIENT RELEVANT FEATURES OF AN OSCILLATING POSITIVE EXPIRATORY PRESSURE (OPEP) DEVICE ARE MOST IMPORTANT IN THE REAL WORLD – RESULTS FROM AN INDEPENDENT CLINICAL ASSESSMENT IN UK

A Brace, J Suggett. *Trudell Medical International, Hampshire, UK*

10.1136/thorax-2021-BTSAbstracts.173

Introduction and Objectives OPEP devices can be used to manage a number of different respiratory conditions by providing airway clearance therapy to mobilize and clear excess mucus from the lungs. This assessment investigated the relative importance of a number of different patient relevant features when selecting an OPEP device.

Methods The survey was completed, as part of an independent clinical assessment of an OPEP device (Aerobika*, Trudell Medical International), across 23 UK centres by respiratory physiotherapists. They were asked to note, for each patient, the respiratory condition being managed and to select which device features would be important when selecting an OPEP device for that patient. Up to fourteen different features could be selected and these covered topics related to a) ease of use/cleaning, b) clinical adaptability/evidence and c) device robustness/quality.

Results Data related to 156 individual patients was collected, covering CF, bronchiectasis and COPD conditions. The most important features noted were generally related to device ease of use and associated attributes. These were highest overall and for each specific respiratory condition. Orientation independence and the ability to easily take apart and clean were identified specifically as high rating factors. When the data was analysed by respiratory condition and the top 5 features compared, there was generally agreement across different conditions, although interestingly the attribute 'clinically proven' was of a greater relative importance when selecting for COPD and bronchiectasis patients than for CF and the ability to use at low expiratory flows was higher rated for COPD than the other two conditions.

Conclusions In conclusion, the results reflect the pragmatic and clinically relevant perspective of selecting a device that a patient can easily use and therefore is more likely to use in the real world.

Please refer to page A192 for declarations of interest related to this abstract.

P64 PREVALENCE OF BREATHING PATTERN DISORDERS WITH CHRONIC REFRACTORY COUGH AND THE OUTCOMES OF PHYSIOTHERAPY MANAGEMENT

¹R De Vos, ²H Rupani, ¹T Brown, ¹L Fox, ¹L Wiffen, ¹AJ Chauhan. ¹Portsmouth Hospitals University NHS Trust, Portsmouth, UK; ²University Hospital Southampton NHS Trust, Southampton, UK

10.1136/thorax-2021-BTSAbstracts.174

Background Chronic refractory cough (CRC) is described as a cough that persists despite guideline-based treatment. Once medical management is optimised the mainstay of treatment is to reduce upper airway hypersensitivity. The prevalence of breathing pattern disorders (BPD) with CRC is increasingly recognised and treatment by specialist respiratory physiotherapists (SRP) aims to reduce symptom burden.

Objectives

- To determine the prevalence of comorbid BPD with CRC.
- To assess improvement in cough following SRP input.

Methods We reviewed 34 patients (79.4% female) with CRC referred to a SRP over a 6 month period. Patients were assessed for BPD and treatment included breathing pattern retraining alongside cough management and suppression techniques. Cough severity and impact of cough on quality of life (QOL) was scored on a 10-point visual analogue scale (VAS) pre and post treatment.

Results

- Average length of CRC was 7.8 years (range 1–25 years)
- Patients were reviewed by the same SRP an average of 3 times (range 2–5)
- 33/34 (97%) had a comorbid BPD as assessed by the SRP
- 31/34 completed treatment with 28/31 (90%) reporting improvement in symptoms

Abstract P64 Table 1

	Pre SRP intervention	Post SRP intervention	P value
VAS score for Cough severity (median, range)	6, 3–10	2, 0–10	<0.0001
VAS score for QOL related to cough (median, range)	6, 0–10	2, 0–7	<0.0001

Conclusion BPD commonly coexists with CRC.

SRP intervention in patients with CRC improves symptoms and quality of life related to cough.

SRP should therefore be an integral part of a CRC clinic, with routine assessment for BPD carried out.

P65 REMOTE DELIVERY OPTIONS FOR SELF-MANAGEMENT PROGRAMMES FOR PATIENTS WITH COPD DURING THE COVID-19 PANDEMIC. UPTAKE, COMPLETION AND CLINICAL OUTCOMES

^{1,2}L Houchen-Wolloff, ¹S Ward, ¹EJ Chaplin, ¹NY Gardiner, ^{1,2}SJ Singh. ¹University Hospitals of Leicester, Leicester, UK; ²University of Leicester, Leicester, UK

10.1136/thorax-2021-BTSAbstracts.175

Introduction Face-to-face pulmonary rehabilitation (PR) programmes were largely stopped in the UK in March 2020 due